HLA

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Giovedì, Marzo 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Giovedì, Marzo 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

Withdrawn application: Orencia, 19/02/2024

Retrieved on: 
Mercoledì, Aprile 3, 2024
CD86, Graft-versus-host disease, Gene, Methotrexate, Psoriasis, Letter, Cell, Bone marrow, Risk, Inflammation, Patient, Ageing, Psoriatic arthritis, HSCT, Allele, Joint, Protein, HLA, European Medicines Agency, Arthritis, Syringe, Rheumatism, Agency, Clinical trial, Skin, CD80, Cancer, Immune system, Blood, Calcineurin, Medicine, Vaccine

Withdrawn application: Orencia, 19/02/2024

Key Points: 


Withdrawn application: Orencia, 19/02/2024

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Research, HLA, Nivolumab, Sale, Skin, PRISM, PR, SME, Commercial, PIWIL1, Neoplasm, Research and development, CTA, Melanoma, BMY, HBV, Progression-free survival, Treatment, GMP, Cancer, Bristol Myers Squibb, Convertible, APC, Security (finance), Congress, Circulating tumor DNA, DNA, Immune system, Lung cancer, Total, ESMO, Conference, Safety, Ovary, RECIST, Infection, Oncology, IND, Mum, Conference call, PFS, Note, Annual report, Pro forma, PRAME, Event, Patient, TCR, HIV, Pharmaceutical industry

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points: 
  • Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
  • The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
  • Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
  • Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, SARS-CoV-2, HLA, MD, Infection, Cell, Risk, CTL, Genome, COVID, Patient, Clinical trial, TVGN, Vaccine

TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.

Key Points: 
  • TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.
  • Tevogen plans to assess whether TVGN 489 cells can rapidly eliminate symptoms of Long Covid.
  • Prior to launching the Long COVID clinical trial, Tevogen seeks to address whether Long COVID occurs more commonly with certain HLA types and less commonly with others, or whether Long COVID occurs randomly in the population regardless of HLA.
  • I am highly optimistic that TVGN 489 will offer a meaningful solution for both acute and Long COVID patients,” said Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer.

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Technology, Health, General Health, Public Relations, Investor Relations, Communications, Health Technology, Medical Devices, Genetics, Internet, Mobile, Wireless, Clinical Trials, Hematopoietic stem cell transplantation, Caregiver, Patient, AML, Digital Solutions, ALL, HLA, Chimera, HCT, High, Medicine, Transplant, Prognosis, Cell, HA2, Nucleic acid thermodynamics, MDS, University, Antigen, HA1, Accuracy and precision, Medical device

“Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.

Key Points: 
  • “Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.
  • CareDx will be showcasing its broad portfolio of digital health solutions that address needs in the cellular transplant and therapy ecosystem including workflow management, regulatory reporting, medication management, and remote patient monitoring.
  • Product solution areas include:
    Ottr® Cellular: Designed as a workflow management solution for hematopoietic cellular transplant and cellular therapy centers.
  • Poster 299: Analytical Validation of AlloCell cfDNA - a Highly Sensitive, Precise, and Accurate Cell-Free DNA-Based Test for Allogeneic Cell Therapy Monitoring.

Sigma Debuts 15mm F1.4 Ultra-Wide, 500mm F5.6 Super-Tele Prime Lenses - YouTube Introduction Information at B&H

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Light, Sony, HLA, B&H, Lens, Art, Sport, Element, FLD, SLD, Reproduction, Motion, Environment, Camera

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- B&H is pleased to announce new prime lenses from Sigma's Art and Sports lines for mirrorless cameras: the 15mm f/1.4 DG DN Art and the 500mm f/5.6 DG DN OS Sports lenses. Available in L-mount and Sony E-mount configurations, the pair offers exceptional imaging and professional-grade performance at both ends of the focal-length spectrum.

Key Points: 
  • Sigma expands its Art and Sports lines for mirrorless with a 15mm f/1.4 diagonal fisheye and the handheld-friendly, super-telephoto 500mm f/5.6 lens.
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- B&H is pleased to announce new prime lenses from Sigma's Art and Sports lines for mirrorless cameras : the 15mm f/1.4 DG DN Art and the 500mm f/5.6 DG DN OS Sports lenses.
  • Take a night walk on the wide side with Sigma's latest astro-centric offering, the 15mm f/1.4 DG DN Art lens.
  • Joining two 14mm lenses and a 20mm lens, this bright, ultra-wide prime distinguishes itself as the line's only diagonal fisheye.

Inaugural Award Poised to Advance Treatment Options for Uveal Melanoma Patients

Retrieved on: 
Venerdì, Febbraio 16, 2024
Uveal melanoma, Liver, Melanoma, Research, Doctor of Philosophy, Schepens Eye Research Institute, HLA, Massachusetts Eye and Ear, MD, FDA, MRF, Friends, Food, CURE, Hope, Eye, Frustration, UM, Patient, Family, Disease, Tebentafusp, Education, Nursing

WASHINGTON , Feb. 16, 2024 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) recently announced the winners of the inaugural CURE OM Options Bring Hope Team Science Award: Bruce Ksander, PhD from the Schepens Eye Research Institute; Rizwan Haq MD, PhD from the Dana-Farber Cancer Institute and Margarete Karg, PhD from Massachusetts Eye and Ear Infirmary. The collaborative research project is titled, "Identification of molecular pathways that drive uveal melanoma metastasis." The goal of the team's research is to determine the main factors that drive uveal melanoma (UM) to spread and specifically target the liver, with the hope that this research may guide the development of effective therapeutic interventions. Uveal melanoma is a type of ocular melanoma (OM) and is the most common type of eye cancer in adults that constitutes around 5 of all melanomas. In about half of all UM cases, the disease will spread to other parts of the body. When this occurs, it is almost always fatal.

Key Points: 
  • The collaborative research project is titled, "Identification of molecular pathways that drive uveal melanoma metastasis."
  • Uveal melanoma is a type of ocular melanoma (OM) and is the most common type of eye cancer in adults that constitutes around 5 of all melanomas.
  • The CURE OM Options Bring Hope Team Science Award intends to support an interdisciplinary research team who is researching treatment options for metastatic UM patients not limited by HLA type.
  • To learn more about the CURE OM Options Bring Hope Team Science Award, read here .

Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

Retrieved on: 
Giovedì, Febbraio 15, 2024
Fast Track, Genotype, Autoimmune disease, HLA, FDA, Food, Prevalence, Diabetes, Medicine, Patient, Type 1 diabetes, Diamyd Medical, Failure, Pharmaceutical industry

STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2.

Key Points: 
  • STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2.
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.
  • Fast Track designation is intended to bring promising medicines to patients sooner.
  • "We are very pleased with the FDA's decision to grant Fast Track designation for Diamyd and the potential this provides to accelerate Diamyd's path to entering the US market", says Ulf Hannelius, CEO of Diamyd Medical.

Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

Retrieved on: 
Giovedì, Febbraio 15, 2024
Fast Track, Genotype, Autoimmune disease, HLA, FDA, Food, Prevalence, Diabetes, Medicine, Patient, Type 1 diabetes, Diamyd Medical, Failure, Pharmaceutical industry

STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2.

Key Points: 
  • STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2.
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.
  • Fast Track designation is intended to bring promising medicines to patients sooner.
  • "We are very pleased with the FDA's decision to grant Fast Track designation for Diamyd and the potential this provides to accelerate Diamyd's path to entering the US market", says Ulf Hannelius, CEO of Diamyd Medical.